3 452

Cited 179 times in

Metastatic non–clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria

Authors
 Nils Kroeger  ;  Wanling Xie  ;  Jae-Lyn Lee  ;  Georg A. Bjarnason  ;  Jennifer J. Knox  ;  Mary J. MacKenzie  ;  Lori Wood  ;  Sandy Srinivas  ;  Ulka N. Vaishamayan  ;  Sun-Young Rha  ;  Sumanta K. Pal  ;  Takeshi Yuasa  ;  Frede Donskov  ;  Neeraj Agarwal  ;  Christian K. Kollmannsberger  ;  Min-Han Tan  ;  Scott A. North  ;  Brian I. Rini  ;  Toni K. Choueiri  ;  Daniel Y.C. Heng 
Citation
 CANCER, Vol.119(16) : 2999-3006, 2013 
Journal Title
CANCER
ISSN
 0008-543X 
Issue Date
2013
MeSH
Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use* ; Canada/epidemiology ; Carcinoma, Renal Cell/drug therapy* ; Carcinoma, Renal Cell/mortality* ; Cohort Studies ; Denmark/epidemiology ; Female ; Humans ; Japan/epidemiology ; Kidney Neoplasms/drug therapy* ; Kidney Neoplasms/mortality* ; Male ; Prognosis ; Republic of Korea/epidemiology ; Singapore/epidemiology ; Survival Analysis ; Treatment Outcome ; United States/epidemiology
Keywords
Heng risk criteria ; IMDC risk model ; non-clear cell renal cell carcinoma ; overall survival ; prognostication ; targeted therapies
Abstract
BACKGROUND:
This study aimed to apply the International mRCC Database Consortium (IMDC) prognostic model in metastatic non-clear cell renal cell carcinoma (nccRCC). In addition, the survival outcome of metastatic nccRCC patients was characterized.
METHODS:
Data on 2215 patients (1963 with clear-cell RCC [ccRCC] and 252 with nccRCC) treated with first-line VEGF- and mTOR-targeted therapies were collected from the IMDC. Time to treatment failure (TTF) and overall survival (OS) were compared in groups with favorable, intermediate, and poor prognoses according to IMDC prognostic criteria
RESULTS:
The median OS of the entire cohort was 20.9 months. nccRCC patients were younger (P < .0001) and more often presented with low hemoglobin (P = .014) and elevated neutrophils (P = .0001), but otherwise had clinicopathological features similar to those of ccRCC patients. OS (12.8 vs 22.3 months; P < .0001) and TTF (4.2 vs 7.8 months; P < .0001) were worse in nccRCC patients compared with ccRCC patients. The hazard ratio for death and TTF when adjusted for the prognostic factors was 1.41 (95% CI, 1.19-1.67; P < .0001) and 1.54 (95% CI, 1.33-1.79; P < .0001), respectively. The IMDC prognostic model reliably discriminated 3 risk groups to predict OS and TTF in nccRCC; the median OS of the favorable, intermediate, and poor prognosis groups was 31.4, 16.1, and 5.1 months, respectively (P < .0001), and the median TTF was 9.6, 4.9, and 2.1 months, respectively (P < .0001).
CONCLUSIONS:
Although targeted agents have significantly improved the outcome of patients with nccRCC, for the majority survival is still inferior compared with patients with ccRCC. The IMDC prognostic model reliably predicts OS and TTF in nccRCC and ccRCC patients.
Full Text
http://onlinelibrary.wiley.com/doi/10.1002/cncr.28151/abstract
DOI
10.1002/cncr.28151
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Rha, Sun Young(라선영) ORCID logo https://orcid.org/0000-0002-2512-4531
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/88022
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links